The rate for the latter half of the year brings the full-year average to 23.4% – rising to 24.3% next year and 26% in 2027 – ...

The pressure to execute a flawless drug or therapy launch has never been greater and continues to lay the foundation for long ...

SpliceBio's lead in-house pipeline project is in Stargardt disease, an IRD with no approved therapies that is caused by ...

BMS kickstarted its radiopharma drive last year when it completed a $4.1 billion acquisition of San Diego-based RayzeBio, ...

If that sounds like the storyline to Marvel's latest superhero tale, that's because it is. The publisher's latest custom ...

Makary and Prasad also repeat various themes repeatedly visited by Kennedy on his Make America Healthy Again (MAHA) soapbox, ...

At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.